Vivos Inc. Reports Revenue Growth and Strategic Advancements Amid Ongoing Losses

Vivos Inc. reported its financial results for the six months ended June 30, 2026, revealing a revenue increase to $72,468 from $41,748 in the same period of 2025. Despite this growth, the company experienced a gross loss of $9,738, an improvement from a gross loss of $43,835 in the prior year. The operating loss for the first half of 2026 was $1,200,021, down from $1,538,305 in 2025. The net loss for the period was $2,015,034, compared to a net loss of $1,480,209 in the previous year, indicating ongoing challenges in achieving profitability.

The company’s total assets increased significantly to $2,879,570 as of June 30, 2026, up from $1,867,583 at the end of 2025. This growth was primarily driven by an increase in cash reserves, which rose to $2,336,022 from $1,558,525. Current liabilities decreased substantially to $49,973 from $117,892, reflecting improved management of payables and accrued expenses. Stockholders' equity also saw a notable increase, reaching $2,755,615 compared to $1,660,840 at the end of the previous fiscal year.

Strategically, Vivos Inc. has made significant advancements, including the establishment of Vivos Scientific India LLP, aimed at expanding its manufacturing capabilities and clinical trials in India. The company received FDA approval for its Early Feasibility Investigational Device Exemption (IDE) in July 2026, allowing it to initiate human clinical trials for its RadioGel® product at the Mayo Clinic. This milestone is expected to enhance the company’s regulatory standing and facilitate future product commercialization.

Operationally, Vivos Inc. reported a substantial increase in its IsoPet® animal therapy division, with a 1,200% year-over-year increase in administered therapies in 2025. As of June 30, 2026, the company had 17 certified clinics treating various animal species. The company is focused on expanding its network of certified clinics and enhancing its marketing efforts to drive adoption of IsoPet® therapies. However, the company continues to face liquidity challenges, requiring approximately $3 million annually to maintain operations and an estimated $9 million over the next three years to support ongoing clinical trials and product development.

Looking ahead, Vivos Inc. aims to leverage its recent regulatory approvals and strategic initiatives to enhance its market position. The company plans to utilize proceeds from its Regulation A+ offerings to fund its Precision Radionuclide Therapy™ platform, expand its manufacturing capabilities, and support clinical trials. However, the company acknowledges the need for additional capital to sustain its operations and achieve profitability, emphasizing the importance of securing funding to continue its growth trajectory.